海普瑞:2024年制剂业务毛利率同比下降 受中国集采中标价格下调影响

金融界
08 Apr

金融界4月8日消息, 海普瑞披露投资者关系活动记录表显示,公司2024年制剂业务毛利率同比下降,主要受到中国集采中标价格下调的影响,尽管中国市场销量增加,但集采价格较2023年上半年有所下降,导致整体毛利及毛利率受到较大影响。公司预计,随着成本端价格逐步传导,制剂毛利率在2025年有回暖的表现。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10